Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The Institutional Review Board (IRB) has approved Aurora Spine’s multicentre study of its ZIP Interspinous Fixation Device
  • The device is being developed for patients suffering from back pain due to symptomatic degenerative disc disease
  • The study will involve 100 patients and Aurora Spine expects to see results within the year
  • Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies
  • Aurora Spine (ASG) closed out the day at C$0.81 per share

The Institutional Review Board (IRB) has approved Aurora Spine’s multicentre study of its ZIP Interspinous Fixation Device. 

The device is being developed for patients suffering from back pain due to symptomatic degenerative disc disease.

Aurora Spine has partnered with Celéri Health, a real-world evidence company whose mission is to use patient-centric data to develop Real World Outcomes to accelerate drug and device discovery.

Trent Northcutt, Aurora’s president, CEO, and co-founder, commented,

“We have established a great relationship with Celéri Health for the data portion of our project using their Real World Outcomes platform,” he said.

Vipul Mangal, M.D., an interventional pain specialist from National Spine & Pain Centers, has adopted this therapy in his patients as a minimally invasive alternative approach.

Dr. Mangal commented,

“This device has been revolutionary in my practice as a minimally invasive device to significantly improve function and pain for my patients with back pain.”

Michael A. Fishman, MD, MBA., Director of Research at the Center for Interventional Pain & Spine in Lancaster, PA, also commented on the study.

“This multicenter study will involve 100 patients with results expected this year. The study is designed to demonstrate reproducible outcomes in the real-world with attention to pain, function, and quality of life,” he said.

The IRB is an FDA-registered constituted group that has been formally designated to review and monitor biomedical research involving human subjects.

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Aurora Spine (ASG) closed out the day at C$0.81 per share. 

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.